logo-loader

OncoSil Medical Ltd updates on Pancreatic Cancer Clinical Study

Published: 10:00 28 Nov 2016 AEDT

5750162705_6312fedf6d_o_opt_583b6f1079dde
OncoSil Medical Ltd updates on Pancreatic Cancer Clinical Study.

OncoSil Medical Ltd (ASX:OSL) has provided an update on its global OncoPaC clinical study program.

Highlights:

- Johns Hopkins Hospital and MD Anderson Cancer Centre are the leading U.S. centres;
- Investigational Review Board (IRB) process has commenced and is on-going for these two U.S. centres;
- Guy’s and St Thomas’ Hospitals, London are the leading UK centres; and
- Monash Health has agreed to be the lead Australian centre – ethics submission filed and under review.


Daniel Kenny, chief executive officer, commented:

"I am are delighted with the participation of these four prestigious centres in our global clinical program.

"These centres bring tremendous credibility as well as the benefit of being potential high volume recruitment sites.

"Our team looks forward to working with these centres and their state of the art facilities.

"I am pleased to report that we have another 11 centres in the U.S., UK and Australia currently evaluating the feasibility of participating in our study."

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

12 hours, 58 minutes ago